Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Follow Up of Engerix-B in Newborns of HBeAg+ and HBsAg+ Mothers
NCT00240500Phase 4Completed
- Sponsor
- GSK
- Start
- Oct 2003
- Primary completion
- Nov 2007
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 4, open-label trial of hepatitis b vaccine recombinant in hepatitis B (HBV) (6 arms), sponsored by GSK. Primary endpoints: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations at 20 years, Prevalence of Serological Markers for Hepatitis B Infection at 20 years and 1 more. Started Oct 2003; status: completed.
02
Drugs
hepatitis b vaccine recombinant
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT00240500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240500.